Mercaptopurine rescue after azathioprine-induced liver injury in inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 31, Issue 1, 2010, Pages 120-124

  Bermejo, F ^a,b   LOpez SanromAn A ^c   Algaba, A ^b   Van Domselaar, M ^c   Gisbert, J P ^d   GarcIa GarzOn S ^b   Garrido, E ^c   Piqueras, B ^b   De La Poza, G ^c   Guerra, I ^b  

^a Hospital Universitario de Fuenlabrada ^*  (Spain)

^b HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; MERCAPTOPURINE;

ADULT; ARTICLE; CHOLESTASIS; CLINICAL ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; CROHN DISEASE; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LIVER TOXICITY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; ULCERATIVE COLITIS;

EID: 71449103027     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2009.04132.x     Document Type: Article

References (27)

1. Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev 2000 CD000067.
2. Gisbert JP, Gomollon F, Mate J, Pajares JM. Questions and answers on the role of azathioprine and 6-mercaptopurine in the treatment of inflammatory bowel disease. Gastroenterol Hepatol 2002 25 : 401 415. (Pubitemid 34847185)
3. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989 111 : 641 649.
4. de Jong DJ, Derijks LJ, Naber AH, Hooymans PM, Mulder CJ. Safety of thiopurines in the treatment of inflammatory bowel disease. Scand J Gastroenterol Suppl 2003 38 : 69 72.
5. Gisbert JP, Gonzalez-Lama Y, Mate J. Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review. Am J Gastroenterol 2007 102 : 1518 1527. (Pubitemid 46976279)
6. Hindorf U, Johansson M, Eriksson A, Kvifors E, Almer SHC. Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther 2009 29 : 654 661.
7. Gearry RB, Barclay ML, Burt MJ, Collett JA, Chapman BA. Thiopurine drug AEs in a population of New Zealand patients with inflammatory bowel disease. Pharmacoepidemiol Drug Saf 2004 13 : 563 567.
8. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989 24 : 2 6.
9. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005 19 (Suppl. A 5 36.
10. Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990 11 : 272 276.
11. Travis SP, Stange EF, Lémann M, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006 55 (Suppl I i16 35.
12. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute Technical Review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006 130 : 940 987. (Pubitemid 43374543)
13. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008 371 : 660 667.
14. Shergill AK, Terdiman JP. Controversies in the treatment of Crohn's disease: the case for an accelerated step-up treatment approach. World J Gastro 2008 14 : 2670 2677.
15. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995 123 : 132 142.
16. Bermejo F, Lopez SanRoman A, Taxonera C, et al. Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine-induced pancreatitis. Aliment Pharmacol Ther 2008 28 : 623 628.
17. Romagnuolo J, Sadowski DC, Lalor E, Jewell L, Thomson AB. Cholestatic hepatocellular injury with azathioprine: a case report and review of the mechanisms of hepatotoxicity. Can J Gastroenterol 1998 12 : 479 483.
18. Bastida G, Nos P, Aguas M, et al. Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2005 22 : 775 782.
19. Schwab M, Schaffeler E, Marx C, et al. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics 2002 12 : 429 436.
20. McGovern DP, Travis SP, Duley J, Shobowale-Bakre el M, Dalton HR. Azathioprine intolerance in patients with IBD may be imidazole-related and is independent of TPMT activity. Gastroenterology 2002 122 : 838 839.
21. Domenech E, Nos P, Papo M, Lopez-San Roman A, Garcia-Planella E, Gassull MA. 6-Mercaptopurine in patients with inflammatory bowel disease and previous digestive intolerance of azathioprine. Scand J Gastroenterol 2005 40 : 52 5.
22. Eklund BI, Moberg M, Bergquist J, Mannervik B. Divergent activities of human glutathione transferases in the bioactivation of azathioprine. Mol Pharmacol 2006 70 : 747 754.
23. Gyamfi MA, Wan YJ. The effect of ethanol, ethanol metabolizing enzyme inhibitors, and Vitamin E on regulating glutathione, glutathione S-transferase, and S-adenosylmethionine in mouse primary hepatocyte. Hepatol Res 2006 35 : 53 61.
24. Lopez-Sanroman A, Bermejo F, Carrera E, Garcia-Plaza A. Efficacy and safety of thiopurinic immunomodulators (azathioprine and mercaptopurine) in steroid-dependent ulcerative colitis. Aliment Pharmacol Ther 2004 20 : 161 166.
25. Kiefer K, El-Matary W. 6-Mercaptopurine as an alternative to azathioprine in azathioprine-induced hepatoxicity. Inflamm Bowel Dis 2009 15 : 318 319.
26. Hindorf U, Lindqvist M, Hildebrand P, Fagerberg U, Almer S. AE leading to modification of therapy in a large cohort of patients with inflammatory bowel disease. Aliment Pharmacol Ther 2006 24 : 331 342.
27. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000 118 : 705 713.